,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2017-12-06 06:01:00,"Chicago, IL - December 6, 2017 - Zacks.com announces the list of stocks featured in the Analyst Blog.",0.017898129299283028,0.008712023496627808,0.9733899235725403,neutral,0.00918610580265522
1,2017-12-06 06:01:00,Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.,0.021041298285126686,0.011407552286982536,0.9675511121749878,neutral,0.00963374599814415
2,2017-12-06 06:01:00,"Stocks recently featured in the blog include Home DepotHD , BoeingBA , MerckMRK , AllstateALL and IlluminaILMN .",0.022771896794438362,0.011569473892450333,0.9656586647033691,neutral,0.01120242290198803
3,2017-12-06 06:01:00,"Here are highlights from Tuesday's Analyst Blog:

The Zacks Research Daily presents the best research output of our analyst team.",0.23975257575511932,0.009843643754720688,0.7504038214683533,neutral,0.22990892827510834
4,2017-12-06 06:01:00,"Today's Research Daily features new research reports on 16 major stocks, including Home Depot, Boeing and Merck.",0.036422114819288254,0.009549153037369251,0.9540287852287292,neutral,0.026872962713241577
5,2017-12-06 06:01:00,These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.,0.054846275597810745,0.007339245639741421,0.937814474105835,neutral,0.04750702902674675
6,2017-12-06 06:01:00,"Buy-rated Home Depot 's shares have gained +37.9% year to date, compared with the +31.5% gain of the Zacks Retail Building Products industry, backed by its five-year long trend of beating earnings estimates.",0.9566633701324463,0.025319265201687813,0.018017344176769257,positive,0.9313440918922424
7,2017-12-06 06:01:00,"The company delivered bottom-line beat in third-quarter fiscal 2017, while sales topped estimates for the fifth straight quarter.",0.9310442209243774,0.028892597183585167,0.04006313532590866,positive,0.9021516442298889
8,2017-12-06 06:01:00,"Results gained from strength in core business as well as relentless focus on affording innovative products, boosting interconnected customer experience and driving productivity.",0.9371642470359802,0.014141994528472424,0.04869364947080612,positive,0.9230222702026367
9,2017-12-06 06:01:00,Steady housing market recovery and strong customer demand also remained tailwinds.,0.41334089636802673,0.4791700541973114,0.10748894512653351,negative,-0.06582915782928467
10,2017-12-06 06:01:00,"While hurricane-related activities aided comps growth, gross margins on such sales were significantly below average.",0.020050186663866043,0.9636198878288269,0.016329914331436157,negative,-0.9435697197914124
11,2017-12-06 06:01:00,"This led to a decline in gross margin, which is likely to continue in fiscal 2017.",0.018560631200671196,0.968575656414032,0.012863771989941597,negative,-0.9500150084495544
12,2017-12-06 06:01:00,"Moreover, competition from online retailers may impact performance.",0.03194781765341759,0.7816116809844971,0.1864406019449234,negative,-0.7496638894081116
13,2017-12-06 06:01:00,"Shares of Boeing have surged +78.6% over the past year, outperforming the Zacks Aerospace & Defense sector, which gained +39.2% during the same time period.",0.9494842886924744,0.03011908568441868,0.020396742969751358,positive,0.9193652272224426
14,2017-12-06 06:01:00,"Notably, Boeing is the largest aircraft manufacturer in the world in terms of revenue, orders and deliveries, and one of the largest aerospace and defense contractors.",0.4596852660179138,0.010354508645832539,0.5299602150917053,neutral,0.44933074712753296
15,2017-12-06 06:01:00,"In this regard, the company's 20-year market outlook forecasts commercial jetliner demand to increase by 3.6%.",0.9528864026069641,0.015554811805486679,0.03155876696109772,positive,0.9373316168785095
16,2017-12-06 06:01:00,"Yet, this aerospace company continues to face challenges from order cancellations, stiff competition as well as falling delivery numbers.",0.02643805369734764,0.945465087890625,0.02809685468673706,negative,-0.9190270304679871
17,2017-12-06 06:01:00,"Furthermore, Boeing's 787 Dreamliner's deferred production cost remains a cause of concern.",0.022067919373512268,0.9182311296463013,0.05970092862844467,negative,-0.8961632251739502
18,2017-12-06 06:01:00,"Merck 's shares have underperformed the Zacks Large Cap Pharmaceuticals industry over the last year, losing -6.8% versus +18.5%, as the company has suffered some notable pipeline setbacks this year.",0.027090594172477722,0.9628385901451111,0.01007088739424944,negative,-0.9357479810714722
19,2017-12-06 06:01:00,"Merck enjoys a diversified business across branded drugs, vaccines and animal health.",0.22747384011745453,0.0060293059796094894,0.7664968371391296,neutral,0.2214445322751999
20,2017-12-06 06:01:00,Merck has made significant progress with its pipeline and is working on bringing new products to the market.,0.9167266488075256,0.012010951526463032,0.07126236706972122,positive,0.9047157168388367
21,2017-12-06 06:01:00,New products like Keytruda and Zepatier should continue to contribute meaningfully to the top line.,0.9212912917137146,0.012524315156042576,0.06618444621562958,positive,0.9087669849395752
22,2017-12-06 06:01:00,Keytruda is gaining strong momentum from new indication of first-line lung cancer.,0.9365800023078918,0.015606309287250042,0.047813668847084045,positive,0.9209737181663513
23,2017-12-06 06:01:00,The Keytruda development program also significantly advanced this year with several key regulatory approvals.,0.940843403339386,0.01615375280380249,0.043002791702747345,positive,0.9246896505355835
24,2017-12-06 06:01:00,"Meanwhile, Merck will continue to focus on cost-cutting initiatives to drive the bottom line.",0.8275777697563171,0.013668387196958065,0.1587538719177246,positive,0.8139094114303589
25,2017-12-06 06:01:00,"However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line.",0.09528374671936035,0.08432639390230179,0.8203898668289185,neutral,0.010957352817058563
26,2017-12-06 06:01:00,Rising competition in the immuno-oncology market is also a significant concern.,0.055177539587020874,0.3132378160953522,0.631584644317627,neutral,-0.2580602765083313
27,2017-12-06 06:01:00,Other noteworthy reports we are featuring today include Allstate and Illumina.,0.03704904392361641,0.005645928904414177,0.9573050141334534,neutral,0.03140311688184738
28,2017-12-06 06:01:00,Looking for Stocks with Skyrocketing Upside?,0.09469357132911682,0.09826507419347763,0.807041347026825,neutral,-0.0035715028643608093
29,2017-12-06 06:01:00,Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.,0.41462862491607666,0.01087752915918827,0.5744938254356384,neutral,0.40375110507011414
30,2017-12-06 06:01:00,"Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021.",0.8838319182395935,0.03136736899614334,0.08480073511600494,positive,0.8524645566940308
31,2017-12-06 06:01:00,"Early investors stand to make a killing, but you have to be ready to act and know just where to look.",0.19955629110336304,0.018484661355614662,0.781959056854248,neutral,0.18107162415981293
32,2017-12-06 06:01:00,"See the pot trades we're targeting>>

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.",0.014050446450710297,0.008892985992133617,0.9770565629005432,neutral,0.005157460458576679
33,2017-12-06 06:01:00,Past performance is no guarantee of future results.,0.023727279156446457,0.008731111884117126,0.9675416350364685,neutral,0.01499616727232933
34,2017-12-06 06:01:00,Inherent in any investment is the potential for loss .,0.023265572264790535,0.09617827832698822,0.8805561661720276,neutral,-0.07291270792484283
35,2017-12-06 06:01:00,"This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security.",0.011962415650486946,0.010706594213843346,0.9773310422897339,neutral,0.0012558214366436005
36,2017-12-06 06:01:00,No recommendation or advice is being given as to whether any investment is suitable for a particular investor.,0.01822577603161335,0.008984367363154888,0.9727898240089417,neutral,0.009241408668458462
37,2017-12-06 06:01:00,"It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable.",0.020858757197856903,0.007662615738809109,0.9714785814285278,neutral,0.013196141459047794
38,2017-12-06 06:01:00,All information is current as of the date of herein and is subject to change without notice.,0.01124907098710537,0.013303965330123901,0.9754469990730286,neutral,-0.002054894343018532
39,2017-12-06 06:01:00,Any views or opinions expressed may not reflect those of the firm as a whole.,0.008276145905256271,0.021656149998307228,0.9700676798820496,neutral,-0.013380004093050957
40,2017-12-06 06:01:00,"Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities.",0.009504852816462517,0.012596068903803825,0.9778990745544434,neutral,-0.0030912160873413086
41,2017-12-06 06:01:00,These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs.,0.14585068821907043,0.02033580094575882,0.8338135480880737,neutral,0.1255148947238922
42,2017-12-06 06:01:00,These are not the returns of actual portfolios of stocks.,0.010538044385612011,0.012450686655938625,0.9770112633705139,neutral,-0.0019126422703266144
43,2017-12-06 06:01:00,The S&P 500 is an unmanaged index.,0.022511588409543037,0.0801919475197792,0.8972964882850647,neutral,-0.05768036097288132
44,2017-12-06 06:01:00,Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.,0.01104306522756815,0.014137434773147106,0.9748194813728333,neutral,-0.0030943695455789566
45,2017-12-06 06:01:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
46,2017-12-06 06:01:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069372057914734,0.007019792217761278,0.9422864317893982,neutral,0.04367392882704735
47,2017-12-06 06:01:00,"Click to get this free report

To read this article on Zacks.com click here.",0.020684564486145973,0.03315984085202217,0.9461556077003479,neutral,-0.012475276365876198
48,2017-12-06 06:01:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
